Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 40^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 10:30 a.m. Eastern Time, followed by a question and answer session.

The conference will be held virtually. A live audio-only webcast of Acadia’s presentation and question and answer session, along with accompanying slides, will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through February 11, 2022.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on treating psychosis in patients with dementia, the negative symptoms of schizophrenia and Rett syndrome. Our early-stage development efforts are focused on novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005096/en/